Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results Global development program for JNJ-1900 (NBTXR3) proceeding as...
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2024 Le programme de développement global de JNJ-1900...
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025 Conférence téléphonique et diffusion en direct...
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 Conference call and webcast scheduled...
Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en...
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for...
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference Data...
NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer...
NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie...
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du...
Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지